I am afraid of using aprotinin because they say so?  by Shuhaiber, Jeffrey H.
cated, a clamp-and-sew technique might be a
reasonable alternative, as suggested by Tra-
chiolis and associates.4 In a selected group
initial nonoperative management and stabili-
zation with -blockers while other comor-
bidities are addressed, followed by elective
repair, might be a reasonable option.
John Santosh Kumar Murala, MBBS, MS, MCha
Andrew Numa, MBBS, FRACP, FJFICMb
Peter Grant, MBBS (Hon), FRACS, MBAa
Department of Cardiothoracic Surgerya
Department of Children’s Intensive Careb
Sydney Children’s hospital
High Street
Randwick, NSW 2031
Australia
E-mail: peter.grant@
SESIAHS.HEALTH.NSW.GOV.AU
References
1. Cook J, Salerno C, Krishnadasan B, et al. The
effect of changing presentation and manage-
ment on the outcome of blunt rupture of the
thoracic aorta. J Thorac Cardiovasc Surg.
2006;131:594-600.
2. Kouchoukos NT, Bavaria JE, Coselli JS, et al.
Guidelines for credentialing of practitioners
to perform endovascular stent-grafting of the
thoracic aorta. J Thorac Cardiovasc Surg.
2006;131:530-2.
3. Karmy-Jones R, Hoffer E, Meissner M, et al.
Management of traumatic rupture of the tho-
racic aorta in paediatric patients. Ann Thorac
Surg. 2003;75:1513-7.
4. Trachiolis GD, Sell JE, Pearson GD, et al.
Traumatic thoracic aortic rupture in the pae-
diatric patient. Ann Thorac Surg. 1996;62:
724-31.
doi:10.1016/j.jtcvs.2006.05.044
Reply to the Editor:
We appreciate the kind comments made by
Dr Murala and colleagues, and we agree
with the operative technique and indica-
tions they describe. They have highlighted
an ongoing issue with respect to managing
traumatic aortic disruption in a patient who
has not finished growing. Not only do late
complications of erosion need to be con-
sidered, but we wonder whether the stented
aorta will be prevented from growing, lead-
ing in later life to possible coarcation phys-
iology. Thus as we and others have noted,
endovascular approaches to this problem
need to be incorporated into an algorithm
that includes open repair, medical manage-
ment, or both. We would argue that endo-
vascular stenting be considered if there are
contraindications to operative repair and to
medical management (recognizing that dif-
ferent surgeons and centers might vary in
what is considered a contraindication). Fur-
thermore, because the vast majority of pedi-
atric patients will be candidates only for cuff
extenders or contralateral limbs, these should
be used only if they can be applied predom-
inantly on the “straight” portion of the de-
scending aorta (to minimize endoleak) and if
the proximal points of endografts are not so
close to the left common carotid artery that
any subsequent operation would require an
anterior arch approach.
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I am afraid of using aprotinin
because they say so?
To the Editor:
Cardiothoracic surgeons have become more
aware of the worse outcomes associated with
aprotinin after cardiac surgery, as discussed
in the article by Mangano and colleagues1
published in the New England Journal of
Medicine. It remains an observational study
that, as the authors point out, is in need of
randomized studies. The main concern of
the authors that has not been addressed is
the analysis of a larger sample size in the
aprotinin group compared with that for
other antifibrinolytics. The weighted aver-
age effect of a large sample size can have a
larger effect when outcomes are analyzed.
I will address further potential con-
founding factors by Mangano and col-
leagues.1 The authors did not control for
preoperative hemoglobin count. Zindrou
and associates2 reported on a cohort of
2058 patients and demonstrated that a pre-
operative hemoglobin concentration of 10
g/L or less had a 5-fold higher in-hospital
mortality rate after coronary artery bypass
grafting mortality rates seen in those with a
higher hemoglobin concentration, despite
having had blood transfusions. Maintaining
a patient’s hematocrit value within the nor-
mal range and avoiding extremes is impor-
tant. The main surgical factor that affects
outcome in coronary artery bypass grafting
is anastomosis of the internal thoracic ar-
tery to the left anterior descending artery.
Moreover, the absence of critical disease in
other vessels also affected outcome.3 Man-
gano and associates1 also provided no in-
formation about the mean number of grafts
per patient, perioperative blood loss, blood-
saving techniques, and “transfusion trig-
ger.” These issues are important because
there is a dose-dependent association be-
tween blood transfusion and the develop-
ment of severe postoperative infection and
death in patients undergoing cardiac sur-
Figure 1. Aortogram performed from the right brachial route demonstrating a pseudoan-
eurysm of the proximal descending aorta just distal to the origin of the left subclavian
artery. There is no extravasation.
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gery.4 The authors also mentioned use of
multiple variables that might or might not
be clinically relevant and assigned propen-
sity scores in the outcome models to adjust
for antifibrinolytic use. I believe that such
an analysis is suboptimal to propensity
score matching in quantiles. Surgeons need
to take a closer look and revisit the data
published in this article before banning
aprotinin from their practice.
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About the activation of the
coagulation system during on-pump
and off-pump coronary surgery and
the use of antifibrinolytic drugs
To the Editor:
The results of the study by Paparella
and colleagues1 recently published in the
Journal confirm part of the observations
described in previous reports addressing
the activation of coagulation and fibrinoly-
sis in coronary surgery performed with
(ONCAB) or without (OPCAB) cardiopul-
monary bypass (CPB). However, some of
the statements contained in their “Discus-
sion” section deserve critical consideration.
Because no difference in tissue factor (TF)
“production” was observed in the 2 groups
of patients while prothrombin fragment 1.2
levels were higher in patients undergoing
ONCAB, the authors state that the extrinsic
pathway of coagulation should not be con-
sidered the only trigger for thrombin for-
mation during CPB. Although the intrinsic
pathway might also play a role in thrombin
formation during CPB, the observation of
circulating levels of TF that are not signif-
icantly different does not per se demon-
strate a similar activation of the extrinsic
pathway of coagulation in the 2 groups of
patients. TF is a transmembrane protein
expressed by white blood cells under con-
ditions of activation, and deposition of
such cells in the CPB circuit has been
shown before.2 Therefore plasma levels of
TF might not reflect the true “exposure” of
TF to circulating blood. The authors state
that in patients undergoing OPCAB, ad-
ministration of a heparin dose similar to the
one used during CPB (300 U/kg) elimi-
nates the production of thrombin during the
time of the operation. “Elimination” of
thrombin production would lead to severe
bleeding, which cannot obviously be the
aim of heparin administration. The authors
also state that platelet function, as analyzed
by using an in vitro bleeding test (PFA-
100), is better preserved during OPCAB
surgery than during CPB and that the lack
of CPB and cardiotomy suction, together
with the reduced formation of thrombin,
might explain why platelet function is pre-
served in patients undergoing OPCAB. The
PFA-100 is influenced by the platelet count
and the hematocrit level, which are both
obviously higher in patients undergoing
OPCAB, and by von Willebrand factor lev-
els, which are known to increase postoper-
atively. Thus the PFA-100 can hardly be
considered validated in evaluating platelet
function in the setting of cardiac surgery.
Despite the observation of a similar post-
operative “hypercoagulable” pattern in the
2 groups of patients, the authors also em-
phasize that D-dimer levels are lower in
patients undergoing OPCAB, advising
against the use of antifibrinolytic drugs,
which might increase the risk of vein graft
occlusion in this surgical setting. These
conclusions are in disagreement with the
results previously reported by our group3
and with the clinical observations of the
authors. A similar, although not negligible,
24-hour postoperative bleeding value was
recorded in the 2 groups (total blood loss:
ONCAB, 861.2  340.3 mL; OPCAB,
933.7 382.6 mL). In a pilot study carried
out in patients not receiving antifibrinolytic
drugs, we recorded an average total blood
loss of 850 mL in patients undergoing
ONCAB and 750 mL in patients undergo-
ing OPCAB.3 In a larger study powered to
detect differences in bleeding between pa-
tients undergoing ONCAB and patients un-
dergoing OPCAB randomized to receive
tranexamic acid or placebo, the average
total blood loss was 754 mL and 552 mL in
patients undergoing ONCAB off or on
tranexamic acid treatment and 654 and 375
mL in patients undergoing OPCAB off or
on tranexamic acid treatment, respectively,
with a significant reduction in bleeding for
both groups in the tranexamic acid arm
(P  .006).4 In both studies the difference
in total bleeding observed between patients
undergoing ONCAB and patients undergo-
ing OPCAB was obviously affected by the
different amount of heparin infused in the 2
groups (3 times higher in patients undergo-
ing ONCAB). Moreover, in the same study
we found that tranexamic acid administra-
tion not only significantly reduces periop-
erative bleeding and the need for allogeneic
transfusions both in patients undergoing
ONCAB and patients undergoing OPCAB
but also modulates inflammation, particu-
larly in OPCAB surgery.4 In view of these
certain advantages of antifibrinolytic drugs
and of a procoagulant postoperative state of
uncertain significance,5,6 the advice against
the use of antifibrinolytic agents is, in our
opinion, at least debatable.
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